BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29907593)

  • 1. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
    Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
    Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
    Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
    J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
    Kumar A; Kant S; Singh SM
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways.
    Lee EH; Chung JW; Sung E; Yoon BH; Jeon M; Park S; Chun SY; Lee JN; Kim BS; Kim HT; Kim TH; Choi SH; Yoo ES; Kwon TG; Kang HW; Kim WJ; Yun SJ; Lee S; Ha YS
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/β‑catenin/N‑cadherin axis.
    Kim CJ; Terado T; Tambe Y; Mukaisho KI; Kageyama S; Kawauchi A; Inoue H
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.
    Yu S; Li Y; Ren H; Zhou H; Ning Q; Chen X; Hu T; Yang L
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):207-215. PubMed ID: 33221963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
    Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
    Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
    Huang Y; Luan T; Bao X; Fu S; Li N; Li H; Wang H; Li C; Wang J
    Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
    Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
    J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate.
    Piao L; Sidhu VK; Fang YH; Ryan JJ; Parikh KS; Hong Z; Toth PT; Morrow E; Kutty S; Lopaschuk GD; Archer SL
    J Mol Med (Berl); 2013 Mar; 91(3):333-46. PubMed ID: 23247844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents.
    Mallinson JE; Constantin-Teodosiu D; Glaves PD; Martin EA; Davies WJ; Westwood FR; Sidaway JE; Greenhaff PL
    J Physiol; 2012 Dec; 590(24):6389-402. PubMed ID: 23045346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LKB1 Represses ATOH1 via PDK4 and Energy Metabolism and Regulates Intestinal Stem Cell Fate.
    Gao Y; Yan Y; Tripathi S; Pentinmikko N; Amaral A; Päivinen P; Domènech-Moreno E; Andersson S; Wong IPL; Clevers H; Katajisto P; Mäkelä TP
    Gastroenterology; 2020 Apr; 158(5):1389-1401.e10. PubMed ID: 31930988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression.
    Gopal K; Saleme B; Al Batran R; Aburasayn H; Eshreif A; Ho KL; Ma WK; Almutairi M; Eaton F; Gandhi M; Park EA; Sutendra G; Ussher JR
    Am J Physiol Heart Circ Physiol; 2017 Sep; 313(3):H479-H490. PubMed ID: 28687587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sodium Dichloroacetate Alone and in Combination Therapies on Lung Tumor Growth and Metastasis.
    Al-Azawi A; Sulaiman S; Arafat K; Yasin J; Nemmar A; Attoub S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-modality imaging to assess metabolic response to dichloroacetate treatment in tumor models.
    Neveu MA; De Preter G; Joudiou N; Bol A; Brender JR; Saito K; Kishimoto S; Grégoire V; Jordan BF; Krishna MC; Feron O; Gallez B
    Oncotarget; 2016 Dec; 7(49):81741-81749. PubMed ID: 28082726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
    Wang X; Zhang F; Wu XR
    Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
    Kluza J; Corazao-Rozas P; Touil Y; Jendoubi M; Maire C; Guerreschi P; Jonneaux A; Ballot C; Balayssac S; Valable S; Corroyer-Dulmont A; Bernaudin M; Malet-Martino M; de Lassalle EM; Maboudou P; Formstecher P; Polakowska R; Mortier L; Marchetti P
    Cancer Res; 2012 Oct; 72(19):5035-47. PubMed ID: 22865452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.